Tumorigenicity
CorestemChemon Partners with ATG Lifetech to Expand Organoid and Transcriptomics Capabilities
CorestemChemon; ATG Lifetech; organoids; transcriptomics; preclinical CRO; drug discovery; predictive analytics; tumorigenicity; FDA/EMA regulatory pathways; liver organoids; heart organoids; blood-brain barrier models